1. Home
  2. URI vs ARGX Comparison

URI vs ARGX Comparison

Compare URI & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URI
  • ARGX
  • Stock Information
  • Founded
  • URI 1997
  • ARGX 2008
  • Country
  • URI United States
  • ARGX Netherlands
  • Employees
  • URI N/A
  • ARGX N/A
  • Industry
  • URI Diversified Commercial Services
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • URI Consumer Discretionary
  • ARGX Health Care
  • Exchange
  • URI Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • URI 63.1B
  • ARGX 51.1B
  • IPO Year
  • URI 1997
  • ARGX 2017
  • Fundamental
  • Price
  • URI $838.94
  • ARGX $851.85
  • Analyst Decision
  • URI Buy
  • ARGX Strong Buy
  • Analyst Count
  • URI 14
  • ARGX 17
  • Target Price
  • URI $973.69
  • ARGX $866.53
  • AVG Volume (30 Days)
  • URI 558.8K
  • ARGX 376.8K
  • Earning Date
  • URI 10-22-2025
  • ARGX 10-30-2025
  • Dividend Yield
  • URI 0.85%
  • ARGX N/A
  • EPS Growth
  • URI 1.51
  • ARGX N/A
  • EPS
  • URI 38.83
  • ARGX 23.27
  • Revenue
  • URI $15,986,000,000.00
  • ARGX $3,683,281,000.00
  • Revenue This Year
  • URI $5.57
  • ARGX $85.93
  • Revenue Next Year
  • URI $5.25
  • ARGX $35.17
  • P/E Ratio
  • URI $21.75
  • ARGX $33.14
  • Revenue Growth
  • URI 6.73
  • ARGX 92.98
  • 52 Week Low
  • URI $525.91
  • ARGX $510.06
  • 52 Week High
  • URI $1,021.47
  • ARGX $855.46
  • Technical
  • Relative Strength Index (RSI)
  • URI 29.53
  • ARGX 68.04
  • Support Level
  • URI $850.00
  • ARGX $812.79
  • Resistance Level
  • URI $883.48
  • ARGX $850.66
  • Average True Range (ATR)
  • URI 26.75
  • ARGX 23.45
  • MACD
  • URI -11.95
  • ARGX -1.87
  • Stochastic Oscillator
  • URI 2.16
  • ARGX 96.58

About URI United Rentals Inc.

United Rentals is the world's largest equipment rental company, principally operating in the US and Canada. It has 16% share in a highly fragmented market serving general industrial (49%), commercial construction (46%), and residential construction (5%). The company operates a $21 billion fleet of equipment, including aerial platforms, forklifts, excavators, trucks, power generators, and various other materials serving local and national accounts from nearly 1,600 locations in North America and 100 abroad. It has pursued a strategy of bundling specialty rental capabilities to offer its customers more advanced solutions in addition to its core equipment rental business, supporting its ambitions to become a one-stop shop for customers and enhance and maintain its margin profile.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: